Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $5.94 million. The enterprise value is -$315,542.
Important Dates
The last earnings date was Wednesday, August 13, 2025, after market close.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 9.46 million shares outstanding. The number of shares has increased by 64.15% in one year.
Current Share Class | 9.46M |
Shares Outstanding | 9.46M |
Shares Change (YoY) | +64.15% |
Shares Change (QoQ) | +40.03% |
Owned by Insiders (%) | 2.14% |
Owned by Institutions (%) | 4.31% |
Float | 9.26M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 42.65 |
Forward PS | n/a |
PB Ratio | 1.11 |
P/TBV Ratio | 1.27 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.07
Current Ratio | 6.07 |
Quick Ratio | 5.96 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,019.15 |
Financial Efficiency
Return on equity (ROE) is -90.03% and return on invested capital (ROIC) is -59.38%.
Return on Equity (ROE) | -90.03% |
Return on Assets (ROA) | -43.96% |
Return on Invested Capital (ROIC) | -59.38% |
Return on Capital Employed (ROCE) | -92.21% |
Revenue Per Employee | $24,034 |
Profits Per Employee | -$1.63M |
Employee Count | 3 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.92% in the last 52 weeks. The beta is 1.63, so Silo Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.63 |
52-Week Price Change | -48.92% |
50-Day Moving Average | 0.65 |
200-Day Moving Average | 0.99 |
Relative Strength Index (RSI) | 45.49 |
Average Volume (20 Days) | 354,796 |
Short Selling Information
The latest short interest is 67,438, so 0.71% of the outstanding shares have been sold short.
Short Interest | 67,438 |
Short Previous Month | 134,766 |
Short % of Shares Out | 0.71% |
Short % of Float | 0.73% |
Short Ratio (days to cover) | 0.31 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$4.90 million in losses. Loss per share was -$1.00.
Revenue | 72,102 |
Gross Profit | 66,264 |
Operating Income | -5.17M |
Pretax Income | -3.60M |
Net Income | -4.90M |
EBITDA | n/a |
EBIT | -5.17M |
Loss Per Share | -$1.00 |
Full Income Statement Balance Sheet
The company has $6.26 million in cash and n/a in debt, giving a net cash position of $6.26 million or $0.66 per share.
Cash & Cash Equivalents | 6.26M |
Total Debt | n/a |
Net Cash | 6.26M |
Net Cash Per Share | $0.66 |
Equity (Book Value) | 4.92M |
Book Value Per Share | 0.57 |
Working Capital | 5.32M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -5.19M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Full Cash Flow Statement Margins
Gross Margin | 91.90% |
Operating Margin | -7,164.96% |
Pretax Margin | -6,789.22% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Silo Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -64.15% |
Shareholder Yield | -64.15% |
Earnings Yield | -82.35% |
FCF Yield | n/a |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on September 15, 2022. It was a reverse split with a ratio of 1:50.
Last Split Date | Sep 15, 2022 |
Split Type | Reverse |
Split Ratio | 1:50 |
Scores
Silo Pharma has an Altman Z-Score of -3.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -3.41 |
Piotroski F-Score | 2 |